Trial Title: An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Trial Therapeutic Area: CNS

Trial Country Location(s): Global

Trial Patient Population:
18 Years   -   65 Years,  Genders Eligible for Study:  Both

Investigator Requirments:

Trial Inclusion/Exclusion Criteria:

Inclusion

• The subject has a current primary diagnosis of schizophrenia or schizoaffective disorder; specifically, an acute exacerbation with prominent "active phase" symptoms, as described in DSM-IV-TR criteria (and confirmed by the SCID I/P). Subjects with schizophrenia may belong to any of the following subtypes: paranoid, disorganized, catatonic, or undifferentiated
• The subject has a PANSS total score of >= 60
• The subject has a score of >= 4 ("moderate") on at least 2 out of the following 5 PANSS positive symptoms: delusions, conceptual disorganization, hallucinatory behavior, grandiosity, suspiciousness/persecution

Exclusion

• The subject has any condition that is likely to interfere with his/her ability to complete the study and all the study-related procedures (e.g., blindness, deafness, language difficulties, sensory or motor deficits)
• The subject has any condition which is likely to interfere significantly with the absorption, distribution, metabolism or excretion of the active treatment, including: malabsorption syndromes, previous GI surgery, active peptic ulcer disease, chronic GI disease etc.; evidence suggesting impaired kidney function (e.g., raised urea or creatinine with albuminuria or hematuria); any condition affecting plasma proteins (e.g., multiple myeloma, chronic medical illness)

Person of Contact Info:
Jeanne Martin
Phone: 847-938-7814